title: CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease.
abstract: Expression of CD27 on malignant plasma cells (PC) (CD138+CD38++) was analysed in a cross-sectional study of bone marrow (BM) samples from multiple myeloma (MM) patients (n = 28), monoclonal gammopathy of undetermined significance (MGUS) patients (n = 6) and BM PC from healthy donors (n = 4). MM PC expressed CD27 with a variable, lower intensity pattern compared with the consistent high expression in MGUS and healthy donors. MM patients in complete clinical remission displayed a higher percentage of CD27+ PC compared with patients at diagnosis, relapse or in partial remission. In MM, loss of CD27 correlated with loss of CD19 (R2 = 0.4, P < 0.0001). Human MM cell lines (n = 9) did not express CD27 whereas de novo plasma cell leukaemia (PCL) (n = 3) had a high expression. Re-analysis of a cDNA microarray data set, generated from newly diagnosed MM patients (n = 74), demonstrated that the MM subgroup with the highest prevalence of poor prognostic factors had the lowest CD27 mRNA expression. Fluorescence-activated cell sorting and allele-specific oligonucleotide polymerase chain reaction showed that both CD27+ and CD27- PC subpopulations in MM can belong to the clonal disorder. In conclusion, CD27 is heterogeneously expressed on MM PC and loss of CD27 expression might have prognostic value in MM.
authors.affiliation: Department of Cell Biology, Histology and Immunology Section, University Hospital, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
authors.forename: Jeroen E J
authors.initials: JE
authors.lastname: Guikema
authors.forename: Sjoerd
authors.initials: S
authors.lastname: Hovenga
authors.forename: Edo
authors.initials: E
authors.lastname: Vellenga
authors.forename: Jelle J
authors.initials: JJ
authors.lastname: Conradie
authors.forename: Wayel H
authors.initials: WH
authors.lastname: Abdulahad
authors.forename: Roelof
authors.initials: R
authors.lastname: Bekkema
authors.forename: Jan W
authors.initials: JW
authors.lastname: Smit
authors.forename: Fenghuang
authors.initials: F
authors.lastname: Zhan
authors.forename: John
authors.initials: J
authors.lastname: Shaughnessy
authors.forename: Nicolaas A
authors.initials: NA
authors.lastname: Bos
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000032:analysis; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD / Q000032:analysis; D016022:Case-Control Studies; D006801:Humans; D016130:Immunophenotyping; D008562:Membrane Glycoproteins; D009101:Multiple Myeloma / Q000276:immunology*; D020411:Oligonucleotide Array Sequence Analysis; D010265:Paraproteinemias / Q000276:immunology; D010950:Plasma Cells / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000032:analysis*
chemical_list: D015703:Antigens, CD; D008562:Membrane Glycoproteins; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1